Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis

Carla, Adrien; Pereira, Bruno; Boukail, Hanifa; Audard, Jules; Piñol-Domenech, Nathalie; Carvalho, Manuela De; Blondonnet, Raïko; Zhai, Ruoyang; Morand, Dominique; Lambert, Céline; Sapin, Vincent; Ware, Lorraine B.; Calfee, Carolyn S.; Bastarache, Julie A.; Laffey, John G.; Juffermans, Nicole P.; Bos, Lieuwe D. J.; Artigas, Antonio; Rocco, Patrícia Rieken Macêdo; Matthay, Michael A.; McAuley, Daniel F.; Constantin, Jean-Michel; Jabaudon, Matthieu

doi:10.1186/s12931-020-01337-9

Cited by 13 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences were observed in the frequency of these diseases among positive and negative patients (Fisher's exact test, all p > 0.05). According to the American Thoracic Society guidelines [ 17 ], none of our patients had severe respiratory distress criteria.…”

Section: Resultsmentioning

confidence: 99%

Impact of COVID-19 on a brain damage unit

Romero

Bravo-Martín²,

Oliva-Navarrete³

et al. 2021

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Aim To report on the impact of COVID-19 on a brain damage unit. Methods We reviewed the records of all patients admitted to our brain damage unit. The study included all the significant clinical events from the first RT-PCR assay (April 8th, 2020) for SARS-CoV-2 to the day all patients tested negative (June 8th, 2020). Results Of the 20 patients (14 men) (age 57.7 ± 14.9; 2–71 months after brain damage; all with a Rankin scale > 4), 16 tested positive for SARS-CoV-2 and remained positive for a mean of 32.3 days (ranging from 26 to 61). One patient died from COVID-19, while 12 patients were asymptomatic and three suffered mild pneumonia without acute respiratory distress syndrome. All patients received prophylactic subcutaneous heparin. Intravenous methylprednisolone was prescribed for three patients with bilateral pneumonia with excellent results. Conclusions Most positive cases (93.7%) were not severe. The good outcome was most likely due to the use of phylactic anticoagulation therapy, the early use of methylprednisolone for pneumonia, and the previously reported immunosuppression amid patients with brain damage. This study hopes to encourage further study into brain damage immunity.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of COVID-19 on a brain damage unit

Romero

Bravo-Martín²,

Oliva-Navarrete³

et al. 2021

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

show abstract

“…According to the American Thoracic Society guidelines [ 8 ], among the 16 patients having confirmed SARS-CoV-2 infection, 10 patients had severe infection and 6 patients had non severe infection. The patients with severe infection were significantly older (mean age, 61.1 years vs 48.4 years; P <0 .001) and presented other disorders, such as hypertension (10 vs 5), and other typical COVID-19 symptoms such as fever (10 vs 5) and respiratory problems (7 vs 5), if compared with no severe infection subjects.…”

Section: Resultsmentioning

confidence: 99%

The impact of the SARS-COV2 infection on the disorder of consciousness rehabilitation unit

et al. 2021

View full text Add to dashboard Cite

Background and objective Disorders of consciousness include coma (cannot be aroused, eye remain closed), vegetative state—VS (can appear to be awake, but unable to purposefully interact) and minimally conscious state—MCS (minimal but definite awareness). The objective of this study is to assess the impact of the SARS-CoV-2 infection on the Disorder of Consciousness (DOC) Rehabilitation Unit. Methods This is a retrospective, longitudinal, descriptive, observational, pilot study. We consecutively enrolled 18 patients (age range: 40–72 years, 9 females and 9 males), from three to five months after a brain injury. They were grouped into VS (n = 8) and MCS (n = 10). A confirmed case of COVID-19 was defined as a positive result on high-throughput sequencing or real-time reverse-transcription polymerase chain reaction analysis of throat swab specimens. We collected data of lung Computed Tomography (CT) and laboratory exams. DOC patients who were positive for SARS-CoV-2 were classified into severe and no severe infected group, according to the American Thoracic Society guidelines. Results A total of 18 hospitalized patients with (16) and without confirmed (2) SARS-CoV-2 infection were included in the analysis. After one month, a follow-up clinical evaluation reported that one patient died, one patient was transferred from Covid Unit to Emergency Unit and 3 patients were resulted negative to double swab and they returned to Rehabilitative Unit. Significant differences were reported about hypertension, cardiac disease and respiratory problems between the patients with severe infection and patients without severe infection (P< 0.001). The laboratory findings, such as blood cell counts (P < 0.001), C-reactive protein, D-dimer, potassium and vitamin D levels, seemed to be considered as useful prognostic predictors. Conclusions To our knowledge, this is the first longitudinal study on a sample of chronic DOC patients affected by SARS-CoV-2. This study may offer important new clinical information on COVID-19 for management of DOC patients. Our findings showed that for the subjects with severe infection due to COVID-19, rapid clinical deterioration or worsening could be associated with clinical and laboratory findings, which could contribute to high mortality rate. During the COVID-19 epidemic period, the clinicians should consider all the reported risk factors to avoid delayed diagnosis or misdiagnosis and to prevent the infection transmission in DOC Rehabilitation Unit.

show abstract

“…Where possible, serial non-invasive imaging approaches as reported in some macaque studies (Table 1) are also useful for tracking the time course of pulmonary oedema development. It is notable that some patients with COVID-19 ARDS have more limited oedema with severe hypoxaemia (Gattinoni et al, 2020), and so additional measurements of lung perfusion (pulmonary dead space fraction or ventilation perfusion scans) in animals may also be useful for better understanding of COVID-19 as disease sub-phenotypes may be also be present within animal models (Carla et al, 2020).…”

Section: Demonstration Of Ards-like Lung Pathology In Animalsmentioning

confidence: 99%

Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology

Cleary

Pitchford

Amison

et al. 2020

British J Pharmacology

170

177

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 infections has led to a substantial unmet need for treatments, many of which will require testing in appropriate animal models of this disease. Vaccine trials are already underway, but there remains an urgent need to find other therapeutic approaches to either target SARS-CoV-2 or the complications arising from viral infection, particularly the dysregulated immune response and systemic complications which have been associated with progression to severe COVID-19. At the time of writing, in vivo studies of SARS-CoV-2 infection have been described using macaques, cats, ferrets, hamsters, and transgenic mice expressing human angiotensin I converting enzyme 2 (ACE2). These infection models have already been useful for studies of transmission and immunity, but to date only partly model the mechanisms involved in human severe COVID-19. There is therefore an urgent need for development of animal models for improved evaluation of efficacy of drugs identified as having potential in the treatment of severe COVID-19. These models need to reproduce the key mechanisms of COVID-19 severe acute respiratory distress syndrome and the immunopathology and systemic sequelae associated with this disease. Here, we review the current models of SARS-CoV-2 infection and COVID-19-related disease mechanisms and suggest ways in which animal models can be adapted to increase their usefulness in research into COVID-19 pathogenesis and for assessing potential treatments.

show abstract

Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis

Cited by 13 publications

References 56 publications

Impact of COVID-19 on a brain damage unit

Impact of COVID-19 on a brain damage unit

The impact of the SARS-COV2 infection on the disorder of consciousness rehabilitation unit

Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology

Contact Info

Product

Resources

About